AstraZeneca’s shot is among the most affordable available and forms a bulk of deliveries to poorer nations under the WHO-backed Covax initiative, which aims to confirm the vaccines get to all parts of the world.
Several countries suspended the rollout over blood clot fears while some nations begin warning of another virus wave. The Netherlands and Ireland joined a bunch of nations temporarily halting the utilization of the vaccine following reports of blood coagulation and low platelet count in Norway and Denmark.
The Netherlands became the latest country to suspend the utilization of the COVID-19 vaccine, after reports from Denmark and Norway about possible serious side effects.
Ireland’s health officials recommended suspending the utilization of the AstraZeneca vaccine after reports of blood coagulation and lower platelet counts in Norway and Denmark.
Norway’s health professionals said the country had reports of individuals “bleeding under the skin” and “severe cases of blood clots or brain hemorrhages in younger people” who had received the shot.
The World Health Organization declared AstraZeneca’s Covid-19 vaccine safe.
AstraZeneca said that there was no evidence of increased risk of blood clots from its vaccine, after a review of safety data of individuals vaccinated with its vaccine.
“A careful review of all available safety data of over 17 million people vaccinated within the international organization and also the UK with the COVID-19 vaccine of AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia, in any defined age group, gender, and batch or in any particular country,” the company said.
Ireland, Netherlands, Denmark, Norway, and Iceland have suspended the utilization of the vaccine, while Austria stopped using a batch of shots last week.
Some countries have decided to carry out a deeper review of post-vaccination side effects from the AstraZeneca shot although no cases of blood clots are reported there.
However, Pakistan is using only the Chinese vaccine Sinopharm during the third wave of the pandemic.